CranRichPAC (Vaccinium macrocarpon)

CranRichPAC is a standardized cranberry extract (Vaccinium macrocarpon) concentrated in A-type proanthocyanidins (PACs), primarily tetramers (49%) and pentamers (37%), which inhibit P-fimbriated Escherichia coli from adhering to uroepithelial cell surfaces. This bacterial anti-adhesion mechanism, rather than direct antimicrobial activity, is the primary proposed pathway for its urinary tract health support.

Origin & History

CranRichPAC is a branded cranberry extract derived from Vaccinium macrocarpon (American cranberry), native to North America. It is produced as a standardized concentrate focusing on low-polarity fractions rich in proanthocyanidins (PACs), extracted via methods yielding a pH of 2.4–2.6 with no added substances, meeting United States Pharmacopoeia standards for organic acids.

Historical & Cultural Context

Vaccinium macrocarpon has historical use in North American traditional medicine, though specific duration or systems are not detailed for CranRichPAC. General cranberry species were traditionally used for urinary issues.

Health Benefits

• May support urinary tract health through bacterial anti-adhesion properties (evidence quality: indirect/general cranberry data only)
• Contains proanthocyanidins (tetramers 49%, pentamers 37%) with potential antioxidant activity (evidence quality: chemical analysis only)
• Rich in organic acids including quinic (≥0.9%), citric (≥0.9%), and malic (≥0.7%) acids (evidence quality: compositional data)
• Contains triterpenoids like ursolic acid (372.97 mg/g) with anti-inflammatory potential (evidence quality: in vitro mechanisms)
• Provides phenolic compounds including epicatechin (2.45–4.46 mg/100g) and flavonols (evidence quality: analytical data only)

How It Works

CranRichPAC's A-type proanthocyanidins (primarily tetramers and pentamers) interfere with the adhesion of P-fimbriated Escherichia coli to uroepithelial glycoprotein receptors, specifically blocking mannose-resistant hemagglutination pathways critical to bacterial colonization. The organic acids present, including quinic and citric acid, may mildly acidify urine, creating a less hospitable environment for bacterial proliferation. Additionally, the PAC fraction exhibits free-radical scavenging activity by donating hydrogen atoms to neutralize reactive oxygen species, though this antioxidant pathway is secondary to the anti-adhesion mechanism in the context of urinary health.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses were found for CranRichPAC in the available research. The EMA assessment report summarizes broader Vaccinium macrocarpon evidence but notes insufficient data for authoritative claims on UTIs or other conditions, with no study designs or outcomes specified for this branded form.

Clinical Summary

Direct clinical evidence for CranRichPAC as a branded ingredient is limited, with available data largely extrapolated from general cranberry extract and cranberry juice trials rather than proprietary formulation studies. Meta-analyses of cranberry products in urinary tract infection (UTI) prevention, such as a 2012 Cochrane review of 24 studies (n=4,473), found modest but inconsistent reductions in symptomatic UTI recurrence, particularly in women with recurrent UTIs. A key challenge in interpreting this evidence is that PAC content and A-type linkage specificity vary widely across cranberry products, and CranRichPAC-specific randomized controlled trials with defined PAC dosages and quantified outcomes have not been published in peer-reviewed literature to date. The evidence quality for this ingredient currently remains indirect, derived from chemical characterization and class-level cranberry research.

Nutritional Profile

CranRichPAC is a concentrated cranberry (Vaccinium macrocarpon) extract standardized primarily for proanthocyanidin (PAC) content rather than macronutrient delivery. Key compositional data: Proanthocyanidins are the primary bioactive fraction, consisting of tetramers (~49%) and pentamers (~37%), with smaller proportions of trimers and higher oligomers; total PAC content is standardized per batch (typically expressed as mg PAC per gram of extract using DMAC assay methodology). Organic acids are a defining feature: quinic acid (≥0.9%), citric acid (≥0.9%), and malic acid (≥0.7%) by weight, contributing to the characteristic tart profile and potential urinary pH modulation. Polyphenol broader profile includes flavonols (quercetin, myricetin glycosides), anthocyanins (cyanidin, peonidin, and delphinidin derivatives), and hydroxycinnamic acids (chlorogenic, caffeic acids) at trace-to-minor concentrations typical of dried cranberry extracts. Vitamin C is present in fresh cranberry (~13 mg/100g fruit) but concentration in this extract form is not standardized and likely variable depending on processing. Mineral content is minimal at typical extract doses; potassium, manganese, and copper are present in whole cranberry but are not primary features of this concentrated PAC fraction. Fiber and macronutrients are negligible at functional serving sizes of this extract. Bioavailability note: Cranberry PACs, particularly A-type linkage proanthocyanidins (characteristic of Vaccinium species and distinguishing them from grape/apple B-type PACs), have limited systemic absorption; primary activity is considered luminal/mucosal, particularly within the urinary tract epithelium via anti-adhesion mechanisms. Metabolites including phenolic acids (hippuric acid, benzoic acid derivatives) are detectable in urine following ingestion, confirming some degree of gut microbial metabolism and absorption.

Preparation & Dosage

No clinically studied dosage ranges are available for CranRichPAC specifically. General cranberry extracts lack standardization specifics tied to trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

D-mannose, vitamin C, probiotics (Lactobacillus species), uva ursi

Safety & Interactions

CranRichPAC is generally well tolerated at typical supplemental doses; the most commonly reported side effects from cranberry extracts include mild gastrointestinal discomfort, nausea, and diarrhea, particularly at higher doses. Clinically significant interaction with warfarin (Coumadin) has been documented for cranberry products broadly, with case reports and pharmacokinetic studies suggesting cranberry constituents may inhibit CYP2C9-mediated warfarin metabolism, potentially elevating INR and bleeding risk; concurrent use warrants medical supervision. Individuals with a history of calcium oxalate kidney stones should exercise caution, as cranberry extracts can increase urinary oxalate excretion. Safety data in pregnancy and lactation is insufficient to make definitive recommendations, and consultation with a healthcare provider is advised before use during these periods.